glp 1 and prostate cancer Glucagon-like peptide receptor agonists risk: advancing precision medicine through mechanistic understanding and clinical evidence | Biomarker Research GLP-1s appear to cut cancer

Very interesting paper on an important topic SGLT2is, GLP-1RAs and nsMRAs has significantly transformed clinical guidelines in recent decades shiowing numerous positive including CV and nephroprotection In type 2 diabetes, early evidence suggests that integrating these treatments may offer superior survival and cardiovascular outcomes compared to using single agents

Tirzepatide, a dual GIP/GLP-1 agonist, has demonstrated superior weight loss efficacy, reshaping prescriber preferences in obesity management

Deciding between the injection and pill

Prasad, F

A portion of that loss comes from lean muscle tissue, which is what primarily burns calories